ADMA Biologics Inc (ADMA) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Biotechnology
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $8.64 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Negative news sentiment (-0.67).
ADMA Biologics manufactures and commercializes plasma-derived biologics ASCENIV and BIVIGAM (IVIG for primary immunodeficiency) and Nabi-HB (Hepatitis B immune globulin) at its FDA-licensed fractionation facility in Boca Raton, FL with 600,000-liter annual capacity. Revenue... Read more
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $8.64 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Negative news sentiment (-0.67). Chart setup: Death cross, below all MAs, RSI 28, MACD bearish. Score 6.6/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — ADMA Biologics Inc
Latest news
- Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance — Yahoo Finance negative
- Investigation into ADMA Biologics for Potential Securities Fraud - Intellectia AI — Intellectia AI negative
- ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Research - MarketBeat — MarketBeat negative
- ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday - MarketBeat — MarketBeat neutral
- ADMA Biologics Fair Value call delivered 50% gain despite volatility - Investing.com — Investing.com positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $8.64 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Negative news sentiment (-0.67). Chart setup: Death cross, below all MAs, RSI 28, MACD bearish. Prior stop was $8.03. Score 6.6/10, moderate confidence.
Take-profit target: $14.24 (+65.0% upside). Prior stop was $8.03. Stop-loss: $8.03.
Leverage penalty (D/E 1.1): -0.5; Negative news sentiment (-0.67); Negative momentum.
ADMA Biologics Inc trades at a P/E of 12.7 (forward 8.2). TrendMatrix value score: 8.9/10. Verdict: Sell.
10 analysts cover ADMA with a consensus score of 4.0/5. Average price target: $17.
What does ADMA Biologics Inc do?ADMA Biologics manufactures and commercializes plasma-derived biologics ASCENIV and BIVIGAM (IVIG for primary...
ADMA Biologics manufactures and commercializes plasma-derived biologics ASCENIV and BIVIGAM (IVIG for primary immunodeficiency) and Nabi-HB (Hepatitis B immune globulin) at its FDA-licensed fractionation facility in Boca Raton, FL with 600,000-liter annual capacity. Revenue comes from product sales and plasma collection operations; the company projects >$635M annual revenue potential in 2026 from the Boca Facility.